Abstract
Intravenous drug users (IVDUs) constitute the largest risk group among patients with chronic hepatitis C (1,2). Current guidelines include controversial recommendations regarding HCV therapy in IVDUs (3,4). Several studies involving IVDUs on methadone maintenance have reported positive treatment outcomes comparable to those seen in non-addicts (5,6). Data on the frequency of contraindications and on prognostic factors in IVDUs are limited, however. This information is vital for future guidelines and therapeutic approaches in opiate replacement programmes. Using data from the Swiss Hepatitis C Cohort Study, our aim was to compare drug addicts and non-drug addicts with respect to factors impacting treatment eligibility and prognosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
